Science

Bisantrene is a small molecule anti-cancer drug which has potential as both a low dose, highly targeted precision oncology agent and a high dose, less cardiotoxic chemotherapeutic. History of Bisantrene Bisantrene was originally developed by Lederle Laboratories in the 1970s as a lower cardiotoxic alternative to the anthracyclines. Lederle trialled Bisantrene on a wide range of cancers in the 1980s (more than 40 clinical trials) and it showed particular promise in leukemias, breast cancer and ovarian cancer. Bisantrene was studied in a large Phase III breast cancer trial in the late…

Latest News

+

22 June 2021 – Race Oncology Limited (“Race”) is pleased to announce it has executed an agreement with The Sheba…

Race Oncology presented to the MST Access Australian Micro & Small Caps Conference 2021 on the 17th June 2021. https://youtu.be/vnfteBUgN-w

Contract signed to support Race’s Phase 2 relapsed/refractory Acute Myeloid Leukemia (AML) trial at the Chaim Sheba Medical Center in…